Meritz Securities emerging as major investor in biotech industry The brokerage house invests $42 mil in three biotech firms in three months
Translated by Kim So-in 공개 2022-02-11 08:16:06
이 기사는 2022년 02월 11일 08:04 thebell 에 표출된 기사입니다.Meritz Securities is emerging as a big player in the biotech industry, making investments worth billions of won over the last three months.
Meritz Securities has made principal investments totaling 50 billion won ($42 million) in three biotech firms - Huinno, ImmuneOncia Therapeutics, and Therabest - from October to December 2021, more than 15 billion won in each firm, according to industry sources said.
Huinno is a healthcare startup developing wearable solutions. Yuhan Corp became the second largest shareholder of the company two years ago. Meritz Securities made a pre-initial public offering (pre-IPO) investment in Huinno in December 2021, valuing the company at 250 billion won. The valuation grew 10 times since Yuhan made its investment. SL Investment, KTB Network, Korea Development Bank, A Ventures, and A1 Ventures also participated in the pre-IPO funding.
ImmuneOncia is a joint venture formed by Yuhan and Nasdaq-listed Sorrento Therapeutics. The company raised 24.5 billion won in a pre-IPO placement in January, which valued the company at about 250 billion won. Meritz Securities, Yuhan, the largest shareholder of ImmuneOncia, Premier Partners, K2 Investment Partners, Shinvestor & Partners, BNH Investment, E& Investment, and Hanyang Securities participated in the funding round.
Therabest develops induced pluripotent stem cell (iPSC)-derived NK cell therapy. Yuhan is also the largest shareholder of the company. Meritz Securities joined a Series C funding round in November 2011, valuing Therabest at 180 billion won. Other investors included DS Asset, DA Value Investment, and Cloud IB Investment.
Meritz Securities’ investments in the biotech companies are led by Kim Jae-kyo, vice president of the brokerage firm’s investment & development division. Kim served as director and head of global strategy division at Yuhan, where he handled mergers and acquisitions and investments in biotech firms at home and abroad.
Meritz Securities plans to make investments with an emphasis on development. It will consider ways to maximize a company's technology and expand its valuation, instead of simply injecting capital.
“We aim to make investments that would open the way for biotech firms with technology to enhance their competitiveness,” said an official at Meritz Securities. “We plan to create a virtuous cycle that promotes trust in K-Bio through investments focusing on development.”(Reporting by Eun-jin Choi)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재 및 재배포 금지 >
최신뉴스 in 전체기사
- KT&G, 찻잔속 태풍 '행동주의 공세' 성장 플랜 속도낸다
- 백복인 KT&G 사장 "매출 증대 '경영 효율성' 제고 최우선"
- 이엔플러스, '2차전지 주역' 강태경 각자 대표 선임
- [코스닥 주총 돋보기]티에스아이 사외이사, 이사회 1회 출석당 400만원 '꿀보직'
- 한국알콜 행동주의 통했다…트러스톤 이사회 입성 성공
- 새 최대주주 맞은 '아우딘퓨쳐스', 화장품+신사업 밸류업 시동
- [증권사 IB, 유상증자 비즈니스 전략]KB증권, 코스닥 기업 집중 전략...SME본부까지 신설
- [증권사 PF-ABCP 긴급점검]한국증권, 신용보강 확 줄였지만 '브릿지론' 부담가중
- 대규모 차입부담 두산테스나, 믿을맨은 중장기 성장성
- [넘버원 K-가전 기술]위닉스, 50년 탑티어 '열교환기'의 힘
Translated by Kim So-in 의 다른 기사 보기
더벨 서비스 문의
02-724-4102유료 서비스 안내